A 26-Week, Multi-Center, Open-label, Randomized, Parallel-group Study to Evaluate the Efficacy and Safety of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-Term Intensive Insulin Therapy: Basal Insulin Based Treatment (With Prandial OADs Combination) Versus Twice-daily Premixed Insulin

Trial Profile

A 26-Week, Multi-Center, Open-label, Randomized, Parallel-group Study to Evaluate the Efficacy and Safety of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-Term Intensive Insulin Therapy: Basal Insulin Based Treatment (With Prandial OADs Combination) Versus Twice-daily Premixed Insulin

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin glulisine (Primary) ; Acarbose; Insulin aspart; Metformin; Repaglinide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms SWITCH
  • Sponsors Sanofi
  • Most Recent Events

    • 20 Feb 2018 Planned End Date changed from 1 Sep 2019 to 7 Nov 2019.
    • 20 Feb 2018 Planned primary completion date changed from 1 Sep 2019 to 7 Nov 2019.
    • 05 Feb 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top